Interleukin-27 (Interleukin 27)

A heterodimeric cytokine composed of the IL-27p28 and EBI3 subunits. It is produced primarily by antigen-presenting cells after stimulation by microbial products or inflammatory mediators.

Also Known As:

Networked: 993 relevant articles (79 outcomes, 216 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hunter, Christopher A: 27 articles (11/2021 - 01/2004)
2.	Yoshimoto, Takayuki: 21 articles (01/2018 - 02/2004)
3.	Yoshida, Hiroki: 17 articles (02/2020 - 03/2005)
4.	Liu, Yang: 14 articles (01/2022 - 05/2016)
5.	Bai, Xue-Feng: 13 articles (01/2022 - 01/2008)
6.	Cao, Ju: 12 articles (01/2021 - 06/2010)
7.	Imamichi, Tomozumi: 11 articles (01/2021 - 03/2007)
8.	Feng, Lin: 11 articles (08/2020 - 05/2016)
9.	Jiang, Wei-Dan: 11 articles (08/2020 - 05/2016)
10.	Kuang, Sheng-Yao: 11 articles (08/2020 - 05/2016)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2015 - "Since we first reported the antitumor efficacy of IL-27 in 2004, accumulating evidence obtained by several groups using a variety of preclinical mouse models indicates that IL-27 possesses potent antitumor activity against various types of tumors through multiple mechanisms depending on the characteristics of individual tumors without apparent adverse effects." 05/01/2013 - "Overall, our results suggest that IL-27 may be able to modify interactions between prostate tumor and bone microenvironment cells and thus could be used as a multifunctional therapeutic for restoring bone homeostasis while treating metastatic prostate tumors." 12/01/2013 - "Our results suggest that IL-27 can be effective in reducing tumor growth, can help normalize bone structure, and can promote enhanced accumulation of effector cells in prostate tumors. " 12/01/2011 - "Our results suggest that IL-27 can be effective in reducing tumor growth and can help enhance accumulation of effector cells in prostate tumors in vivo. " 03/15/2009 - "The combination of WT T cells and IL-27 signal-defective DCs may have therapeutic potential against tumors."
2.	Infections 07/01/2015 - "Here we demonstrate that infection with African trypanosomes of IL-27 receptor-deficient (IL-27R-/-) mice results in severe liver immunopathology and dramatically reduced survival as compared to wild-type mice. " 10/01/2014 - "Neutralisation of IL-27 in septic mice significantly improved survival and clearance of bacteria from the lungs of septic mice infected with P aeruginosa, and direct application of recombinant IL-27 could increase susceptibility to P aeruginosa infection. " 12/01/2013 - "Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection." 01/01/2016 - "Association of Interleukin-27 rs 153109 Single Nucleotide Polymorphism with Spontaneous Resolution of Hepatitis C Virus - Genotype 4a Infection in Egyptian Patients." 01/01/2022 - "In the current study, the mouse model was used to evaluate the impact of interleukin-27 (IL-27) and its receptor signaling on the susceptibility of the female genital tract to chlamydial infection. "
3.	Inflammation (Inflammations) 01/01/2023 - "While extensive studies investigated the major target cells of IL-27 mediating its functions, the source of IL-27 especially during tissue specific autoimmune inflammation has not formally been examined. " 04/01/2020 - "Previous study shows that IL-27 inhibits airway inflammation in asthmatic mice. " 01/01/2020 - "Impact from nodule derived IL-27 on systemic or synovial inflammation in RA remains unknown and further study of these implications is required. " 01/01/2019 - "This study was to explore a novel anti-inflammatory role and cellular/molecular mechanism of IL-27 in allergic inflammation. " 10/04/2013 - "Our study suggests that IL-27 has the potential to ameliorate overwhelming inflammation in patients with RA through a reciprocal regulation of Th17 and Treg cells. "
4.	Prostatic Neoplasms (Prostate Cancer) 01/01/2022 - "Conclusion: 4-1BB antibody and IL-27 improved NKG2D agonist function in NK cells against prostate cancer cells." 01/01/2019 - "Taken together, this study demonstrates a potential role for IL-27 in the treatment of prostate cancer." 01/01/2022 - "Aims: To enhance the cytotoxicity of natural killer (NK) cells against prostate cancer cells via NKG2D agonist, with 4-1BB antibody and IL-27 combination. " 01/01/2022 - "4-1BB antibody enhances cytotoxic activity of natural killer cells against prostate cancer cells via NKG2D agonist combined with IL-27." 01/01/2019 - "Using DU145 and PC3 cell lines as models of prostate cancer, we investigated whether IL-27 and IFN-γ affect TLR3-mediated cell death. "
5.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2018 - "In this study, we evaluated the efficacy of adeno-associated viral vector (AAV)-delivered IL-27 (AAV-IL-27) and IL-30 (AAV-IL-30) in a murine model of MS. We found that one single administration of AAV-IL-27, but not AAV-IL-30 completely blocked the development of experimental autoimmune encephalomyelitis (EAE). " 04/01/2012 - "In this study, we have evaluated the development of experimental autoimmune encephalomyelitis (EAE) in EBI3-deficient mice that lack both IL-27 and IL-35. " 01/01/2019 - "IL-27 signaling in Tregs was necessary, as transferring Tregs deficient in IL-27Rα or Lag3, a downstream molecule induced by IL-27, was unable to protect mice from experimental autoimmune encephalomyelitis. " 01/01/2017 - "We immunized wild-type (WT) and IL-27 receptor (WSX-1) knockout mice with MOG35-55 for induction of experimental autoimmune encephalomyelitis and intravenously (i.v.) injected them with MOG35-55 after onset of disease to induce i.v. tolerance. " 10/01/2013 - "We found that interleukin 27 (IL-27) signaling in mouse DCs limited the generation of effector cells of the TH1 and TH17 subsets of helper T cells and the development of experimental autoimmune encephalomyelitis (EAE). "

Related Drugs and Biologics

1.	Cytokines
2.	Interleukin-23 (Interleukin 23)
3.	Interleukin-17 (Interleukin 17)
4.	Interleukin-10 (Interleukin 10)
5.	Biomarkers (Surrogate Marker)
6.	Proteins (Proteins, Gene)
7.	Interleukin-33
8.	Vaccines
9.	p38 Mitogen-Activated Protein Kinases
10.	Interleukin-12 (IL 12)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Drug Therapy (Chemotherapy)
4.	Secondary Prevention
5.	Intranasal Administration